Bellevue Group’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $670K | Buy |
3,653
+88
| +2% | +$16.2K | 0.02% | 102 |
|
|
2025
Q4 | $627K | Sell |
3,565
-648
| -15% | -$106K | 0.01% | 124 |
|
|
2025
Q3 | $590K | Buy |
4,213
+3,811
| +948% | +$515K | 0.01% | 112 |
|
|
2025
Q2 | $50.5K | Hold |
402
| – | – | ﹤0.01% | 139 |
|
|
2025
Q1 | $55K | Sell |
402
-2,250
| -85% | -$322K | ﹤0.01% | 146 |
|
|
2024
Q4 | $406K | Buy |
2,652
+18
| +0.7% | +$3.04K | 0.01% | 127 |
|
|
2024
Q3 | $511K | Sell |
2,634
-3,268
| -55% | -$684K | 0.01% | 129 |
|
|
2024
Q2 | $1.37M | Sell |
5,902
-106
| -2% | -$23K | 0.02% | 114 |
|
|
2024
Q1 | $1.3M | Sell |
6,008
-2,477
| -29% | -$580K | 0.02% | 113 |
|
|
2023
Q4 | $2.2M | Sell |
8,485
-8,829
| -51% | -$2.17M | 0.03% | 106 |
|
|
2023
Q3 | $4.45M | Sell |
17,314
-8,284
| -32% | -$2.22M | 0.07% | 102 |
|
|
2023
Q2 | $7.29M | Buy |
25,598
+894
| +4% | +$266K | 0.1% | 97 |
|
|
2023
Q1 | $6.87M | Sell |
24,704
-3,700
| -13% | -$1.02M | 0.1% | 98 |
|
|
2022
Q4 | $7.87M | Sell |
28,404
-331
| -1% | -$93.5K | 0.1% | 102 |
|
|
2022
Q3 | $7.67M | Buy |
28,735
+6,885
| +32% | +$1.46M | 0.11% | 103 |
|
|
2022
Q2 | $4.46M | Sell |
21,850
-500
| -2% | -$102K | 0.06% | 115 |
|
|
2022
Q1 | $4.71M | Sell |
22,350
-502,650
| -96% | -$109M | 0.05% | 118 |
|
|
2021
Q4 | $126M | Sell |
525,000
-2,000
| -0.4% | -$514K | 1.3% | 23 |
|
|
2021
Q3 | $149M | Sell |
527,000
-1,100
| -0.2% | -$361K | 1.51% | 15 |
|
|
2021
Q2 | $183M | Sell |
528,100
-30,300
| -5% | -$9.18M | 1.79% | 12 |
|
|
2021
Q1 | $156M | Sell |
558,400
-5,600
| -1% | -$1.51M | 1.65% | 15 |
|
|
2020
Q4 | $138M | Buy |
564,000
+555,400
| +6,458% | +$143M | 1.58% | 16 |
|
|
2020
Q3 | $2.44M | Buy |
+8,600
| New | +$2.4M | 0.03% | 140 |
|
|
2020
Q2 | – | Sell |
-8,500
| Closed | -$2.69M | – | 211 |
|
|
2020
Q1 | $2.69M | Buy |
8,500
+8,000
| +1,600% | +$2.43M | 0.05% | 125 |
|
|
2019
Q4 | $148K | Sell |
500
-31,850
| -98% | -$8.84M | ﹤0.01% | 214 |
|
|
2019
Q3 | $7.53M | Buy |
32,350
+2,800
| +9% | +$652K | 0.14% | 97 |
|
|
2019
Q2 | $6.91M | Buy |
29,550
+21,100
| +250% | +$4.87M | 0.12% | 98 |
|
|
2019
Q1 | $2M | Sell |
8,450
-16,800
| -67% | -$5.29M | 0.11% | 109 |
|
|
2018
Q4 | $7.6M | Sell |
25,250
-13,995
| -36% | -$4.47M | 0.5% | 52 |
|
|
2018
Q3 | $13.9M | Sell |
39,245
-100
| -0.3% | -$34.4K | 0.88% | 41 |
|
|
2018
Q2 | $11.4M | Sell |
39,345
-6,855
| -15% | -$1.93M | 0.97% | 38 |
|
|
2018
Q1 | $12.7M | Sell |
46,200
-6,100
| -12% | -$1.89M | 1.25% | 30 |
|
|
2017
Q4 | $16.7M | Sell |
52,300
-6,600
| -11% | -$2.12M | 1.74% | 18 |
|
|
2017
Q3 | $18.4M | Sell |
58,900
-2,600
| -4% | -$770K | 1.93% | 14 |
|
|
2017
Q2 | $16.7M | Buy |
61,500
+8,000
| +15% | +$2.12M | 1.97% | 13 |
|
|
2017
Q1 | $14.6M | Buy |
53,500
+4,500
| +9% | +$1.27M | 1.95% | 15 |
|
|
2016
Q4 | $13.9M | Sell |
49,000
-5,500
| -10% | -$1.63M | 2.85% | 7 |
|
|
2016
Q3 | $17.1M | Hold |
54,500
| – | – | 3.08% | 5 |
|
|
2016
Q2 | $13.2M | Sell |
54,500
-22,040
| -29% | -$5.81M | 2.48% | 7 |
|
|
2016
Q1 | $19.9M | Buy |
+76,540
| New | +$20.2M | 3.62% | 4 |
|
Other funds holding BIIB
VCM
VPM
Bellevue Group's BIIB Position: Q1 2026 in Review
Bellevue Group increased its Biogen (BIIB) stake by 2.5% in Q1 2026, buying an estimated $16.2K and bringing the position to 3,653 shares worth $670K. The position accounts for 0.02% of the portfolio, ranked #102.
Bellevue Group first reported a position in BIIB in Q1 2016 and has held it in 40 quarters since. The position peaked at $183M in Q2 2021. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Bellevue Group held 3,653 shares of Biogen worth $670K as of Q1 2026.
- Bellevue Group bought 88 Biogen shares in Q1 2026, an estimated $16.2K.
- Biogen made up 0.02% of Bellevue Group's portfolio in Q1 2026, its #102 holding.
- Bellevue Group first reported a position in Biogen in Q1 2016 and has held it in 40 quarters since.
- Bellevue Group's Biogen position peaked at $183M in Q2 2021.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.